Sugi Predict

Sugi Predict / Compounds / SCHEMBL644390

SCHEMBL644390

SCHEMBL644390

COc1ccc(Cn2cc(Cl)nc(Cl)c2=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.49
▸ TP53 P04637 2/20 0.49
▸ CMA1 P23946 1/20 0.49
▸ LMNA P02545 1/20 0.48
▸ NPBWR1 P48145 4/20 0.47
▸ GSK3A P49840 1/20 0.46
▸ GSK3B P49841 1/20 0.46
▸ MCHR1 Q99705 1/20 0.43
▸ HDAC3 O15379 1/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ HDAC9 Q9UKV0 1/20 0.42
▸ HDAC5 Q9UQL6 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20902732 0.82 MAPT (0.44) MAPTTP53CMA1LMNANPBWR1
SCHEMBL20893641 0.81 MAPT (0.43) MAPTTP53CMA1LMNANPBWR1
SCHEMBL644097 0.80 ALDH1A1 (0.59) MAPTCMA1LMNAKDM4E
SCHEMBL20893619 0.79 MAPT (0.42) MAPTTP53CMA1LMNANPBWR1
SCHEMBL26128557 0.79 MAPT (0.42) MAPTTP53CMA1LMNANPBWR1
SCHEMBL24323979 0.79 MAPT (0.41) MAPTTP53CMA1LMNANPBWR1
SCHEMBL26129608 0.79 LMNA (0.50) MAPTTP53LMNANPBWR1HDAC3
SCHEMBL27393064 0.77 CMA1 (0.50) MAPTTP53CMA1LMNANPBWR1
SCHEMBL26127236 0.77 BRD4 (0.40) MAPTTP53CMA1LMNANPBWR1
SCHEMBL27261283 0.77 MAPT (0.56) MAPTTP53CMA1LMNANPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076235-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-10 — — WO disclosed
EP-4504739-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2025-02-12 — — EP disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 — — WO disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 — — WO disclosed
WO-2022076622-A2 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
CN-109641915-B Novel 4- (aryl) -N- (3-alkoxyfuro [2,3-B ] pyrazin-2-yl) -piperazine-1-carboxamide derivatives and their antiproliferative effect LSK新药开发有限公司 2021-05-28 — — CN disclosed
EP-3470417-B1 NOVEL 4-(ARYL)-N-(3-ALKOXYFURO[2,3-B]PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVE AND ANTIPROLIFERATIVE EFFECT THEREOF LSK NRDO CO LTD (KR) 2020-11-25 — — EP disclosed
US-10800788-B2 4-(aryl)-N-(3-alkoxyfuro[2,3-b]pyrazin-2-yl)-piperazine-1-carboxamide derivative and antiproliferative effect thereof LSK NRDO CO., LTD. (KR) 2020-10-13 — — US disclosed
US-10800788-B2 4-(aryl)-N-(3-alkoxyfuro[2,3-b]pyrazin-2-yl)-piperazine-1-carboxamide derivative and antiproliferative effect thereof LSK NRDO CO., LTD. (KR) 2020-10-13 — — US disclosed
US-20190337959-A1 Novel 4-(Aryl)-N-(3-Alkoxyfuro[2,3-b]pyrazin-2-yl)-Piperazine-1-Carboxamide Derivative and Antiproliferative Effect Thereof HLB LIFE SCIENCE R&D CO., LTD. (KR) 2019-11-07 — — US disclosed
EP-1931669-A1 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2008-06-18 — — EP disclosed
WO-2008054956-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-05-08 — — WO disclosed
WO-2008054956-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-05-08 — — WO disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 — — WO disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 — — WO disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 — — WO disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337959-A1 Novel 4-(Aryl)-N-(3-Alkoxyfuro[2,3-b]pyrazin-2-yl)-Piperazine-1-Carboxamide Derivative and Antiproliferative Effect Thereof MKI67, API5, CCAR2 MAPT 4750/4885TP53 77/4885CMA1 3676/4885
US-20070117816-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 MAPT 1908/4885TP53 446/4885CMA1 1159/4885
US-10800788-B2 4-(aryl)-N-(3-alkoxyfuro[2,3-b]pyrazin-2-yl)-piperazine-1-carboxamide derivative and antiproliferative effect thereof MKI67, AADAC, API5 MAPT 4787/4885TP53 82/4885CMA1 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.